| Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer NW Mabe, DB Fox, R Lupo, AE Decker, SN Phelps, JW Thompson, ... The Journal of clinical investigation 128 (10), 4413-4428, 2018 | 51 | 2018 |
| Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1 NW Mabe, M Huang, GN Dalton, G Alexe, DA Schaefer, AC Geraghty, ... Nature cancer 3 (8), 976-993, 2022 | 49 | 2022 |
| RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence CC Lin, NW Mabe, YT Lin, WH Yang, X Tang, L Hong, T Sun, J Force, ... Cell Death & Differentiation 27 (7), 2234-2247, 2020 | 42 | 2020 |
| Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence A Walens, J Lin, JS Damrauer, B McKinney, R Lupo, R Newcomb, DB Fox, ... Nature communications 11 (1), 5017, 2020 | 37 | 2020 |
| G9a promotes breast cancer recurrence through repression of a pro-inflammatory program NW Mabe, NMG Garcia, SE Wolery, R Newcomb, RC Meingasner, ... Cell reports 33 (5), 2020 | 28 | 2020 |
| The ETS transcription factor ETV6 constrains the transcriptional activity of EWS–FLI to promote Ewing sarcoma DY Lu, JM Ellegast, KN Ross, CF Malone, S Lin, NW Mabe, NV Dharia, ... Nature Cell Biology 25 (2), 285-297, 2023 | 21 | 2023 |
| Regulator of G protein signaling 6 protects the heart from ischemic injury BR Rorabaugh, B Chakravarti, NW Mabe, SL Seeley, AD Bui, J Yang, ... Journal of Pharmacology and Experimental Therapeutics 360 (3), 409-416, 2017 | 21 | 2017 |
| Gαi2-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart RE Waterson, CG Thompson, NW Mabe, K Kaur, JN Talbot, RR Neubig, ... Cardiovascular research 91 (1), 45-52, 2011 | 21 | 2011 |
| Foxo-dependent Par-4 upregulation prevents long-term survival of residual cells following PI3K–Akt inhibition JS Damrauer, SN Phelps, K Amuchastegui, R Lupo, NW Mabe, A Walens, ... Molecular Cancer Research 16 (4), 599-609, 2018 | 19 | 2018 |
| VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system J So, NW Mabe, B Englinger, KH Chow, SM Moyer, S Yerrum, MC Trissal, ... JCI insight 7 (19), 2022 | 15 | 2022 |
| Myocardial fibrosis, inflammation, and altered cardiac gene expression profiles in rats exposed to a predator-based model of posttraumatic stress disorder BR Rorabaugh, NW Mabe, SL Seeley, TS Stoops, KE Mucher, CP Ney, ... Stress 23 (2), 125-135, 2020 | 14 | 2020 |
| Pharmacological targeting of the cancer epigenome NW Mabe, JA Perry, CF Malone, K Stegmaier Nature Cancer 5 (6), 844-865, 2024 | 3 | 2024 |
| VRK1 is required in VRK2-methylated cancers of the nervous system J So, NW Mabe, B Englinger, SM Moyer, MC Trissal, JG Marques, J Kwon, ... bioRxiv, 2021.12. 28.474386, 2021 | 2 | 2021 |
| The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma CF Malone, NW Mabe, AB Forman, G Alexe, KL Engel, YJC Chen, ... Science Advances 10 (22), eadm9449, 2024 | 1 | 2024 |
| Regulator of G protein signaling protein 6 (RGS6) protects the heart from ischemic injury B Rorabaugh, N Mabe, S Seeley, A Bui, J Yang, R Neubig, R Fisher The FASEB Journal 29, 1026.8, 2015 | 1 | 2015 |
| Abstract A062 Therapeutic targeting of the SAGA KAT module impairs MYCN-amplified neuroblastoma growth through reduction of the MYCN oncogenic gene expression program NW Mabe, CF Malone, AB Forman, G Alexe, KL Engel, YJC Chen, ... Cancer Research 84 (17_Supplement), A062-A062, 2024 | | 2024 |
| Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets NM Kendsersky, M Odrobina, NW Mabe, A Farrel, L Grossmann, M Tsang, ... bioRxiv, 2024.06. 27.600865, 2024 | | 2024 |
| 244 Targeting gangliosides in pediatric cancer GN Dalton, WJ Kim, NW Mabe, M Huang, MC Rotiroti, AM Tousley, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Abstract PR003: Lineage plasticity dictates responsiveness to anti-GD2 therapy in neuroblastoma NW Mabe, M Huang, DA Schaefer, GN Dalton, G Digiovanni, G Alexe, ... Cancer Research 82 (23_Supplement_2), PR003-PR003, 2022 | | 2022 |
| Synthetic lethality of VRK1 in VRK2-methylated cancers J So, N Mabe, B Englinger, J Kwon, B Shim, M Filbin, K Stegmaier, ... Cancer Research 82 (12_Supplement), 2147-2147, 2022 | | 2022 |
